Skip to main content

Loss of Pregnancy in a Patient with Chronic Myeloid Leukemia During Treatment with Nilotinib

Audiocasts - Original Research

Justin Arnall, PharmD, discusses the clinical significance of his research and case study on, “Loss of Pregnancy in a Patient with Chronic Myeloid Leukemia During Treatment with Nilotinib.”

Related Items
Ambulatory Hematology/Oncology Pharmacist Impact on Insurance Denials and Medication Access in an Academic Medical Center
JHOP - October 2027 Vol 17, No 5 published on August 17, 2026 in Original Research, Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols
Outcomes in Early-Stage Triple-Negative Breast Cancer With Dose-Dense Doxorubicin and Cyclophosphamide as Part of Pembrolizumab-Based Regimens
JHOP - October 2027 Vol 17, No 5 published on August 7, 2026 in Original Research, Case Reports, Breast Cancer, Chemotherapy, Immunotherapy
Impact on Safety and Efficacy of Same-Day Administration of Pegfilgrastim in Patients Receiving Continuous 5-Fluorouracil Infusion
JHOP - April 2027 Vol 17, No 2 published on July 30, 2026 in Original Research, Adverse Events, Infusion Issues, Chemotherapy
Incidence of Hypersensitivity Reactions With Rapid Rituximab Infusions for Classical Hematology Indications
JHOP - June 2027 Vol 17, No 3 published on July 27, 2026 in Original Research, Adverse Events, Infusion Issues, Chemotherapy
Extending the Microbiologic Stability of Single-Dose Vials of High-Cost Medications to 28 Days Using a Closed-System Drug-Transfer Device
JHOP - December 2027 Vol 17, No 6 published on July 22, 2026 in Original Research, Cost of Care, Monoclonal Antibodies, Practical Issues in Pharmacy Management
Evaluation of Post-Nadir Granulocyte Colony-Stimulating Factor in Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy With a Hypomethylating Agent and Venetoclax
JHOP - February 2027 Vol 17, No 1 published on July 13, 2026 in Original Research, Chemotherapy, Leukemia
Improving Amivantamab Premedication Compliance by Implementing a Provider Notification
JHOP - February 2027 Vol 17, No 1 published on July 13, 2026 in Original Research, Lung Cancer, Infusion Issues, Oncology Pharmacy Programs/Protocols, Supportive Care
Comparison of Breakthrough Rates of Pneumocystis jirovecii Pneumonia in Adults With Malignancies Receiving Intravenous or Aerosolized Pentamidine for Prophylaxis
JHOP - April 2027 Vol 17, No 2 published on June 22, 2026 in Original Research, Adverse Events
Twice-Daily Bolus Versus Continuous Infusion Intravenous Tacrolimus for Prophylaxis of Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem-Cell Transplant Recipients
JHOP - June 2027 Vol 17, No 3 published on June 17, 2026 in Original Research, Transplant, Infusion Issues, Adverse Events
Incidence of PARP Inhibitor Adverse Events Between Germline Versus Somatic Homologous Recombination Mutations
JHOP - December 2026 Vol 16, No 6 published on June 15, 2026 in Original Research, Adverse Events, PARP Inhibitors, Dose Escalation/Reduction